Wednesday, July 8, 2026

Drug profile · INN

dexrazoxane hydrochloride

dexrazoxane hydrochloride (DEXRAZOXANE HYDROCHLORIDE) is a dna topoisomerase ii inhibitor. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — dexrazoxane hydrochloride
US status
approved
Class
Route
INJECTION
Patents
0
Programs
2
Data quality
0.84

Quick answer

dexrazoxane hydrochloride (DEXRAZOXANE HYDROCHLORIDE) is a dna topoisomerase ii inhibitor. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN dexrazoxane hydrochloride
Brand DEXRAZOXANE HYDROCHLORIDE
Mechanism DNA topoisomerase II inhibitor
Target DNA topoisomerase II
Route INJECTION
Formulation INJECTABLE

Mechanism of action

DNA topoisomerase II inhibitor

Primary target: DNA topoisomerase II

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. UC-0103/1802 Phase 3 · Ningbo Cancer Hospital · Advanced or metastatic soft tissue sarcoma (STS) in patients
  2. Dexmedetomidine Approved · First People's Hospital · Renal Function

Related & competitor drugs

  1. etoposide DNA topoisomerase II inhibitor
  2. teniposide DNA topoisomerase II inhibitor
  3. dexrazoxane Various (V03)

Frequently asked questions

What is dexrazoxane hydrochloride?

dexrazoxane hydrochloride (DEXRAZOXANE HYDROCHLORIDE) is a dna topoisomerase ii inhibitor. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for dexrazoxane hydrochloride?

DEXRAZOXANE HYDROCHLORIDE is a marketed brand name for dexrazoxane hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of dexrazoxane hydrochloride?

dexrazoxane hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.